Les Turner ALS Center at Northwestern Medicine
Les Turner Symposium on ALS
Thank you to everyone who joined us virtually at our 10th Annual Les Turner Symposium on ALS. The Symposium featured presentations from leading ALS clinicians and researchers, including members of our Lois Insolia ALS Clinic at our Les Turner ALS Center at Northwestern Medicine.
Save the date for the 11th Annual Les Turner Symposium on ALS on Monday, November 8, 2021.
To view the 2020 Les Turner Symposium on ALS presentations, click on the titles below.
Keynote Address: Sabrina Paganoni, MD, PhD - “The HEALEY ALS Platform Trial: an innovative and collaborative trial to accelerate the development of effective treatments for ALS”
Clinical Conversations Panel – featuring Colin Franz, MD, PhD, Senda Ajroud-Driss, MD, Sabrina Paganoni, MD, PhD and Lisa F. Wolfe, MD
“On mechanisms and markers of ALS” – Tania Gendron, PhD
“Aggregation-dependent and independent mechanisms of toxicity in TDP-43 and FUS proteinopathies” - Magdalini Polymenidou, PhD
“Novel Insights into the Molecular Mechanisms Driving Neuronal Degeneration in Genetic ALS” - Evangelos Kiskinis, PhD
“Cellular and Molecular Basis of Upper Motor Neuron Degeneration in ALS” - Hande Ozdinler, PhD
“ALS5 and mouse models: Molecular insight into neurodegenerative diseases” - Han-Xiang Deng, MD, PhD
“Using C. elegans genetics to inform human neurodegenerative disease mechanisms” - Brian Kraemer, PhD
Share this Page
Sabrina Paganoni, MD, PhD
Assistant Professor of PM&R at Harvard Medical School
Physician-scientist at the Healey & AMG Center for ALS at Massachusetts General Hospital and at Spaulding Rehabilitation Hospital
Co-principal Investigator of the HEALEY ALS Platform Trial
"The HEALEY ALS Platform Trial: an innovative and collaborative trial to accelerate the development of effective treatments for ALS"
The HEALEY ALS Platform Trial is an innovative trial that was designed to accelerate the path to effective treatments for ALS. A "platform trial" is a clinical trial in which multiple treatments are evaluated simultaneously. New treatments are added to the platform as they become available, thereby decreasing the gap in time from identification of an exciting therapy to testing. This model, already proven successful in the cancer field, will greatly accelerate therapy development of effective and breakthrough treatments for people with ALS by allowing investigators to test more drugs, increase patient access to trials, and reduce the cost by quickly and efficiently evaluating the effectiveness of multiple therapies. The HEALEY ALS Platform Trial opened for enrollment in July 2020 and is enrolling at several sites of the NEALS consortium including the Les Turner ALS Center at Northwestern Medicine.
Tania Gendron, PhD
Assistant Professor of Neuroscience
Mayo Clinic Jacksonville
“On mechanisms and markers of ALS”
Abstract: A repeat expansion in the C9orf72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTD). We discovered that the expanded repeat is atypically translated leading to the formation of proteins of repeating dipeptides. This talk will discuss the potential contribution of dipeptide repeat proteins to disease pathogenesis, and efforts to identify biomarkers to aid in the development of treatments for ALS and FTD.
Magdalini Polymenidou, PhD
Associate Professor for Neurodegenerative Diseases at the Department of Quantitative Biomedicine of the University of Zurich
“Aggregation-dependent and independent mechanisms of toxicity in TDP-43 and FUS proteinopathies”
Abstract: ALS and FTD are fatal and incurable neurodegenerative diseases, characterized by accumulation of pathologic forms of RNA-binding proteins, predominantly TDP-43 and FUS. The functional consequences and potential neurotoxic effects of these FUS or TDP-43 aggregates observed in postmortem brains are debated. Combining structural protein analysis with cellular systems we uncovered a novel and unexpected mechanism that counteracts pathologic aggregation of TDP-43 (1). We also recently discovered that FTD heterogeneity is associated with alternate pathological TDP-43 conformations, reminiscent of prion strains (2). Moreover, we showed that cytoplasmic FUS causes early synaptic defects prior to aggregation in an ALS-FUS mouse model (3). The implications of these studies and their potential for gaining mechanistic insights on TDP-43 and FUS proteinopathies will be discussed.
Evangelos Kiskinis, PhD
New York Stem Cell Foundation – Robertson Investigator
Assistant Professor of Neurology and Physiology
“Novel Insights into the Molecular Mechanisms Driving Neuronal Degeneration in Genetic ALS”
Abstract: ALS can be caused by mutations in genes that encode proteins involved in diverse cellular functions. We have established a series of stem cell based models for a number of genetic subtypes of ALS including C9orf72, SOD1 and NEK1. During the talk I will provide an update on the novel insights into the molecular mechanisms that drive neuronal dysfunction as a result of these mutations in human neurons.
Hande Ozdinler, PhD
Associate Professor of Neurology
“Cellular and Molecular Basis of Upper Motor Neuron Degeneration in ALS”
Abstract: ALS is defined by progressive degeneration of both upper and lower motor neurons. The movement starts in the brain. Therefore, in an effort to build effective and long-term solutions to ALS and other motor neuron diseases, we have to focus our attention to the brain as well. The Ozdinler Lab is one of the pioneers for understanding the biology and pathology of upper motor neurons, which will ultimately lead to the development of novel treatment strategies and identification of novel biomarkers.
Daniela C. Zarnescu, PhD
Professor, University of Arizona
“TDP-43 proteinopathy alters the ribosome association of multiple mRNAs including the glypican Dally-like protein (Dlp)/GPC6”
Abstract: To uncover TDP-43 dependent alterations in translation, we used tagged ribosome affinity purifications in Drosophila models of TDP-43 proteinopathy. Bioinformatics analyses reveal several TDP-43 dependent alterations in ribosome association including the glypican Dally like protein (Dlp), a wingless (Wg/Wnt) signaling component. Here we show that dlp mRNA is insolubilized and Dlp protein is significantly depleted from neuromuscular synapses while steady state transcript levels remain unchanged, consistent with mRNA sequestration and translation inhibition. Surprisingly, we find that Dlp accumulates in cytoplasmic puncta in the Drosophila ventral cord, supporting the possibility of additional intracellular transport deficits, a well-established ALS phenotype. Notably, overexpression of dlp in Drosophila motor neurons is sufficient to mitigate TDP-43 dependent neurodegenerative phenotypes indicating that dlp is a physiologically relevant target of TDP-43. Finally, we show that similar to Dlp in the Drosophila ventral cord, the human ortholog GPC6 forms puncta-like structures in ALS patient spinal cords, further supporting a role for Dlp/GPC6 in TDP-43 induced neurodegeneration.
Han-Xiang Deng, MD, PhD
Research Professor of Neurology
“ALS5 and mouse models: Molecular insight into neurodegenerative diseases”
Abstract: CRISPR/Cas9-mediated gene editing provides potentials for ALS therapeutic development. Efficacy and long-term safety of this approach represent major concerns that remain to be adequately addressed in preclinical studies in vivo. Here, we show that CRISPR/Cas9-mediated genome editing in SOD1-ALS transgenic mice is effective. We did not observe apparent adverse effects in a period of over two years. Detailed analysis of the on-targeting and off-targeting events provides important information for optimization of the targeting design for further therapeutic development.
Brian Kraemer, PhD
Research Associate Professor
University of Washington
“Using C. elegans genetics to inform human neurodegenerative disease mechanisms”
Abstract: The protein TDP-43 forms aggregates in disease-affected neurons in patients with ALS and FTLD-TDP. In addition, mutations in the human gene coding for TDP-43 can cause inherited ALS. By expressing human mutant TDP-43 protein in C. elegans neurons, we have modelled aspects of ALS pathobiology. This animal model exhibits severe motor dysfunction, progressive neurodegeneration, and accumulation of abnormally modified TDP-43 protein. To identify genes regulating TDP-43 toxicity in C. elegans, we have survey all C. elegans genes and found 46 genes that participate in TDP-43 neurotoxicity. We demonstrated that one of them, glucuronic acid epimerase, is decreased in patients with FTLD-TDP suggesting inhibitors of glucuronic acid epimerase could have therapeutic value for ALS and FTLD.
Robert Kalb, MD
Chief of Division of Neuromuscular Disease
Joan and Paul Rubschlager Professor
Director, Les Turner ALS Center at Northwestern Medicine
“Neurons undergo pathogenic metabolic reprograming in modes of familial ALS”
Abstract: Mitochondrial abnormalities are seen in patients with Amyotrophic Lateral Sclerosis (ALS) as well as in vitro and in vivo models of disease. The extent to which such mitochondrial abnormalities lead to impairment in energy production and/or redox state is not fully understood. To examine this issue we studied fuel utilization of pure cortical neuron cultures that were engineered to expression wild type or mutant versions of familial ALS genes, superoxide dismutase or tar DNA binding protein of 43 kDa molecular weight (SOD or TDP43, respectively). Compared with cultures expressing LacZ or the WT human proteins, we find that both mutant SOD and mutant TDP43 lead to a reduction of glucose flux through glycolysis and an even greater reduction in flux through metabolic pathways that are derived from glycolytic intermediates (e.g., pentose phosphate pathway and hexosamine biosynthetic pathway). Despite this alteration in glycolysis, cellular levels of ATP are unaffected. In addition the NAD+/NADH, NADP+/NADPH and GSSG/GSH ratios are normal. These observations imply that neurons re-program their metabolism when expressing disease causing mutant proteins. To undertake causality experiments we deployed a growth fitness assay. Yeast engineered to inducibly express mutant TDP43 have retarded growth. When we manipulated glycolysis gene expression we found that loss of certain isoforms of glycolysis gene suppressed the retarded growth phenotype of TDP43 expressing yeast. These observations suggest that neurons expressing fALS genes lead to a toxic metabolic phenotype that impairs function.
Clinical Conversations Panel
Colin Franz, MD, PhD
Assistant Professor of Physical Medicine & Rehabilitation and Neurology
Senda Ajroud-Driss, MD
Director, Lois Insolia ALS Clinic, Les Turner ALS Center at Northwestern Medicine
Program Director, Neuromuscular Fellowship
Associate Professor of Neurology
Sabrina Paganoni, MD, PhD
Assistant Professor of PM&R at Harvard Medical School
Lisa F. Wolfe, MD
Associate Professor of Medicine (Pulmonary and Critical Care) and Neurology
Thank You to Our Generous Sponsors